Pharma-Bio Serv Financial Results
Pharma-Bio Serv reported Q3 2026 revenues of $2.3 million and a net loss of $14,000, representing a $0.4 million revenue increase and a $190,000 bottom-line improvement over the prior year. For the nine months ended July 31, 2026, the company achieved net income of $252,000 on revenues of $7.3 million.
- Term
- Q3 2026
“Our Q3 results demonstrate the strength of our client relationships and the value of our specialized regulatory and compliance capabilities. By sharpening our focus on markets where our expertise creates a distinct competitive advantage and continuing to drive operating efficiencies, we meaningfully improved our financial performance. We remain confident in our ability to build on this progress and carry that momentum through the final quarter of the year”
Victor Sanchez, Chief Executive Officer